Recent clinical trial data from IDH inhibitors have sparked a new treatment paradigm for IDH1/2-mutant glioma patients, with the IDH inhibitors vorasidenib and ivosidenib demonstrating increased progression-free survival and delaying time to the next intervention.29,30 Trials and drug approval parameters have focused on histologic grade 2 IDH1/2-mutant gliomas without additional molecular characterization beyond 1p/19q status. Here, IDH1 is linked to central nervous system cancer.